Recent Advances on Drug Development and Emerging Therapeutic Agents for Alzheimer's Disease

Overview

Journal Mol Biol Rep

Specialty Molecular Biology

Date 2021 Jun 28

PMID 34181171

Citations 64

Authors

Teeba Athar

K Al Balushi

Shah Alam Khan

Affiliations

Soon will be listed here.

Abstract

Alzheimer's disease (AD) is a neurodegenerative old age disease that is complex, multifactorial, unalterable, and progressive in nature. The currently approved therapy includes cholinesterase inhibitors, NMDA-receptor antagonists and their combination therapy provides only temporary symptomatic relief. Sincere efforts have been made by the researchers globally to identify new targets, discover, and develop novel therapeutic agents for the treatment of AD. This brief review article is intended to cover the recent advances in drug development and emerging therapeutic agents for AD acting at different targets. The article is compiled using various scientific online databases and by referring to clinicaltrials.gov and ALZFORUM (alzforum.org) websites. The upcoming therapies act on one or more targets including amyloids (secretases, Aβ production, amyloid deposition, and immunotherapy), tau proteins (tau phosphorylation/aggregation and immunotherapy) and neuroinflammation in addition to other miscellaneous targets. Despite the tremendous improvement in our understanding of the underlying pathophysiology of AD, only aducanumab was approved by FDA for the treatment of AD in 18 years i.e., since 2003. Hence, it is concluded that novel therapeutic strategies are required to discover and develop therapeutic agents to fight against the century old AD.

Citing Articles

Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines.

Xiao W, Jiang W, Chen Z, Huang Y, Mao J, Zheng W Signal Transduct Target Ther. 2025; 10(1):74.

PMID: 40038239 PMC: 11880366. DOI: 10.1038/s41392-024-02107-5.

TDP43 is a newly identified substrate for PS1, enhancing the expression of APP following cleavage.

Yin H, Wang Y, Ren Z, Xiao Z, Zhang Y, Wang Y Cell Death Discov. 2025; 11(1):76.

PMID: 39988698 PMC: 11847911. DOI: 10.1038/s41420-025-02340-z.

Single-cell sequencing reveals that AK5 inhibits apoptosis in AD oligodendrocytes by regulating the AMPK signaling pathway.

Yang S, Chen B, Zhang J, Zhou X, Jiang Y, Tong W Mol Biol Rep. 2025; 52(1):213.

PMID: 39921763 PMC: 11807073. DOI: 10.1007/s11033-025-10311-x.

Data-driven discovery of associations between prescribed drugs and dementia risk: A systematic review.

Underwood B, Lourida I, Gong J, Tamburin S, Tang E, Sidhom E Alzheimers Dement (N Y). 2025; 11(1):e70037.

PMID: 39839078 PMC: 11747987. DOI: 10.1002/trc2.70037.

DeepDrug as an expert guided and AI driven drug repurposing methodology for selecting the lead combination of drugs for Alzheimer's disease.

Li V, Han Y, Kaistha T, Zhang Q, Downey J, Gozes I Sci Rep. 2025; 15(1):2093.

PMID: 39814937 PMC: 11735786. DOI: 10.1038/s41598-025-85947-7.

References

Smith L, Zhu R, Strittmatter S . Disease-modifying benefit of Fyn blockade persists after washout in mouse Alzheimer's model. Neuropharmacology. 2017; 130:54-61. PMC: 5743608. DOI: 10.1016/j.neuropharm.2017.11.042. View

Liu Y, Weick J, Liu H, Krencik R, Zhang X, Ma L . Medial ganglionic eminence-like cells derived from human embryonic stem cells correct learning and memory deficits. Nat Biotechnol. 2013; 31(5):440-7. PMC: 3711863. DOI: 10.1038/nbt.2565. View

Ettcheto M, Cano A, Manzine P, Busquets O, Verdaguer E, Castro-Torres R . Epigallocatechin-3-Gallate (EGCG) Improves Cognitive Deficits Aggravated by an Obesogenic Diet Through Modulation of Unfolded Protein Response in APPswe/PS1dE9 Mice. Mol Neurobiol. 2019; 57(4):1814-1827. DOI: 10.1007/s12035-019-01849-6. View

Dockens R, Wang J, Castaneda L, Sverdlov O, Huang S, Slemmon R . A placebo-controlled, multiple ascending dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of avagacestat (BMS-708163) in healthy young and elderly subjects. Clin Pharmacokinet. 2012; 51(10):681-93. DOI: 10.1007/s40262-012-0005-x. View

Hey J, Kocis P, Hort J, Abushakra S, Power A, Vyhnalek M . Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain. CNS Drugs. 2018; 32(9):849-861. PMC: 6153967. DOI: 10.1007/s40263-018-0554-0. View

Atri A, Frolich L, Ballard C, Tariot P, Molinuevo J, Boneva N . Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials. JAMA. 2018; 319(2):130-142. PMC: 5833662. DOI: 10.1001/jama.2017.20373. View

Hampel H, Ewers M, Burger K, Annas P, Mortberg A, Bogstedt A . Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry. 2009; 70(6):922-31. View

Wilcock G, Gauthier S, Frisoni G, Jia J, Hardlund J, Moebius H . Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial. J Alzheimers Dis. 2017; 61(1):435-457. PMC: 5734125. DOI: 10.3233/JAD-170560. View

Song Y, Chen X, Wang L, Gao W, Zhu M . Rho kinase inhibitor fasudil protects against β-amyloid-induced hippocampal neurodegeneration in rats. CNS Neurosci Ther. 2013; 19(8):603-10. PMC: 6493451. DOI: 10.1111/cns.12116. View

10.

Killick R, Ribe E, Al-Shawi R, Malik B, Hooper C, Fernandes C . Clusterin regulates β-amyloid toxicity via Dickkopf-1-driven induction of the wnt-PCP-JNK pathway. Mol Psychiatry. 2012; 19(1):88-98. PMC: 3873038. DOI: 10.1038/mp.2012.163. View

11.

Desai R, Varma V, Gerhard T, Segal J, Mahesri M, Chin K . Targeting abnormal metabolism in Alzheimer's disease: The Drug Repurposing for Effective Alzheimer's Medicines (DREAM) study. Alzheimers Dement (N Y). 2020; 6(1):e12095. PMC: 7690721. DOI: 10.1002/trc2.12095. View

12.

Aisen P, Gauthier S, Vellas B, Briand R, Saumier D, Laurin J . Alzhemed: a potential treatment for Alzheimer's disease. Curr Alzheimer Res. 2007; 4(4):473-8. DOI: 10.2174/156720507781788882. View

13.

Sharma R, Pollock K, Hubel A, McKenna D . Mesenchymal stem or stromal cells: a review of clinical applications and manufacturing practices. Transfusion. 2014; 54(5):1418-37. PMC: 6364749. DOI: 10.1111/trf.12421. View

14.

Benek O, Korabecny J, Soukup O . A Perspective on Multi-target Drugs for Alzheimer's Disease. Trends Pharmacol Sci. 2020; 41(7):434-445. DOI: 10.1016/j.tips.2020.04.008. View

15.

Endres K, Fahrenholz F, Lotz J, Hiemke C, Teipel S, Lieb K . Increased CSF APPs-α levels in patients with Alzheimer disease treated with acitretin. Neurology. 2014; 83(21):1930-5. DOI: 10.1212/WNL.0000000000001017. View

16.

Prior M, Dargusch R, Ehren J, Chiruta C, Schubert D . The neurotrophic compound J147 reverses cognitive impairment in aged Alzheimer's disease mice. Alzheimers Res Ther. 2013; 5(3):25. PMC: 3706879. DOI: 10.1186/alzrt179. View

17.

Novak P, Zilka N, Zilkova M, Kovacech B, Skrabana R, Ondrus M . AADvac1, an Active Immunotherapy for Alzheimer's Disease and Non Alzheimer Tauopathies: An Overview of Preclinical and Clinical Development. J Prev Alzheimers Dis. 2018; 6(1):63-69. DOI: 10.14283/jpad.2018.45. View

18.

Maurice T . Protection by sigma-1 receptor agonists is synergic with donepezil, but not with memantine, in a mouse model of amyloid-induced memory impairments. Behav Brain Res. 2015; 296:270-278. DOI: 10.1016/j.bbr.2015.09.020. View

19.

Cai Z, Zhao Y, Zhao B . Roles of glycogen synthase kinase 3 in Alzheimer's disease. Curr Alzheimer Res. 2012; 9(7):864-79. DOI: 10.2174/156720512802455386. View

20.

Burki T . Alzheimer's disease research: the future of BACE inhibitors. Lancet. 2018; 391(10139):2486. DOI: 10.1016/S0140-6736(18)31425-9. View